Genmab — December 2020
-
Hører også Tue blive hængende i vækstsegmentet modsat mange andre, ex. L.
Tvede, som vil gå mod value -
Genmab is a long-term-accumulate kind of stock. It will have ups and downs, but every down is an opportunity because its pipeline is never-ending https://newsfilter.io/articles/genmab-an-european-rd-behemoth-with-long-term-potential-8e3d1f6aad9d5df5fb9c741d17c8644c
-
God morgen.
-
Aktier/tendens: Udsigt til positiv åbning - ratenyt kan løfte Mærsk: https://www.proinvestor.com/investornyt/670673/aktier-tendens-udsigt-til-positiv-abning-ratenyt-kan-lofte-maersk
-
Janssen Submits European Marketing Authorisation Application for Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations https://www.businesswire.com/news/home/20201228005043/en/Janssen-Submits-European-Marketing-Authorisation-Application-for-Amivantamab-for-the-Treatment-of-Patients-with-Metastatic-Non-Small-Cell-Lung-Cancer-with-EGFR-Exon-20-Insertion-Mutations/?feedref=JjAwJuNHiystnCoBq_hl-W8j9Oi60kFTomUxRDB8jhBsNpnJw7dvSfTyni
-
Australia - From 1 January 2021, Darzalex
(daratumumab) will be listed for the first time in combination with bortezomib and dexamethasone, as a second-line treatment for patients with multiple myeloma https://www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/pbs-listings-bring-greater-hope-in-fight-against-multiple-myeloma-and-severe-psoriasis -
yes, and outcomes for these patients are very poor. Filing wasn't really such a surprise; they already flagged that they would. With FDA Breakthrough Therapy Designation in march, they submitted FDA BLA early this month , and recommendation on the request for accelerated assessment was on CHMP agenda this month
-
Remember that Priority Review Voucher Novartis had for Kesimpta, but that didn't really work very well...? Y-mAbs Announces Sale of Priority Review Voucher for $105mio... big business... https://www.marketscreener.com/quote/stock/Y-MABS-THERAPEUTICS-INC-46288936/news/Y-mAbs-Announces-Sale-of-Priority-Review-Voucher-32092094/
-
God morgen.
-
Tirsdagens danske avisuddrag med Egmont, Jysk og Brexit
https://www.proinvestor.com/investornyt/670700/tirsdagens-danske-avisuddrag-med-egmont-jysk-og-brexit -
God morgen
-
Nå, ser da ud til at der er rift om Genmab-aktierne her på falderebet i 2020. Er det mon delvist p.gr. salget af voucheren?Tænker dollarkursen, retssagen med Janssen og hvor meget Horizons midlertidige produktionscut vil betyde for bundlinjen er nogle af de ikke-faglige spørgsmål som kan være med til at forme kursen i det kommende år. Skal vi i 3000 i 2021
?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind